BIAFW

bioAffinity Technologies, Inc. is a biotechnology company focused on commercializing noninvasive tests for the detection of early-stage cancer and lung disease. The Company addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatment. Its segments include Diagnostic Research and Development (R&D) and Laboratory Services. Its Diagnostic R&D segment includes research and development and clinical development on diagnostic tests. Its Laboratory services include all the operations of Village Oaks and PPLS, in addition to sales and marketing of CyPath Lung from bioAffinity. Its first product, CyPath Lung, addresses the need for noninvasive detection of early-stage lung cancer. The CyPath Lung test enables physicians to more confidently identify patients who will likely benefit from timely intervention and more invasive follow-up procedures and those who are likely without lung cancer and should continue routine screening.